TY - JOUR
T1 - Effects of hormonal replacement therapy in postmenopausal hypertensive patients
AU - Affinito, Pietro
AU - Palomba, Stefano
AU - Bonifacio, Marika
AU - Fontana, Dario
AU - Izzo, Raffaele
AU - Trimarco, Bruno
AU - Nappi, Carmine
PY - 2001/10/31
Y1 - 2001/10/31
N2 - Objective: To evaluate the effect of hormonal replacement therapy (HRT) on blood pressure (BP) in postmenopausal hypertensive women. Methods: Sixty women affected by hypertension were enrolled and randomized in two groups of treatment: transdermal continuous HRT in a sequential regimen (group A) and placebo (group P). At baseline, after 3 and 6 months of treatment, the BP with standard sphygmomanometer and with 24-h ambulatory recording method was evaluated in two periods (from day 10 through day 16 of the cycle and from day 20 through day 27 of the cycle). At the same time, we also evaluated total cholesterol, LDL-c, HDL-c, triglycerides, and fibrinogen levels. Results: After 3 and 6 months of treatment, no significant variations of systolic and diastolic BP measured with standard sphygmomanometer were detected in both groups. On the contrary, in group A in comparison with basal values and group P, and without difference between the two phases of treatment, the 24-h recording showed a significant (P <0.05) decrease in BP. No significant variations were detected in group P versus baseline. In particular, we observed in group A at 3 months of treatment a significant (P <0.05) decrease only in daytime BP in comparison with basal values and group P, without difference between the two phases of treatment. Indeed, the decrease in daytime BP was significant (P <0.05) for both systolic and diastolic BP. At 3 and 6 months a significant (P
AB - Objective: To evaluate the effect of hormonal replacement therapy (HRT) on blood pressure (BP) in postmenopausal hypertensive women. Methods: Sixty women affected by hypertension were enrolled and randomized in two groups of treatment: transdermal continuous HRT in a sequential regimen (group A) and placebo (group P). At baseline, after 3 and 6 months of treatment, the BP with standard sphygmomanometer and with 24-h ambulatory recording method was evaluated in two periods (from day 10 through day 16 of the cycle and from day 20 through day 27 of the cycle). At the same time, we also evaluated total cholesterol, LDL-c, HDL-c, triglycerides, and fibrinogen levels. Results: After 3 and 6 months of treatment, no significant variations of systolic and diastolic BP measured with standard sphygmomanometer were detected in both groups. On the contrary, in group A in comparison with basal values and group P, and without difference between the two phases of treatment, the 24-h recording showed a significant (P <0.05) decrease in BP. No significant variations were detected in group P versus baseline. In particular, we observed in group A at 3 months of treatment a significant (P <0.05) decrease only in daytime BP in comparison with basal values and group P, without difference between the two phases of treatment. Indeed, the decrease in daytime BP was significant (P <0.05) for both systolic and diastolic BP. At 3 and 6 months a significant (P
KW - Cardiovascular disease
KW - Hormone replacement therapy
KW - HRT
KW - Hypertension
KW - Postmenopause
UR - http://www.scopus.com/inward/record.url?scp=0035980378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035980378&partnerID=8YFLogxK
U2 - 10.1016/S0378-5122(01)00196-7
DO - 10.1016/S0378-5122(01)00196-7
M3 - Article
C2 - 11684376
AN - SCOPUS:0035980378
VL - 40
SP - 75
EP - 83
JO - Maturitas
JF - Maturitas
SN - 0378-5122
IS - 1
ER -